QPS Bioanalysis of Small Molecules, Biologics and Cell & Gene Therapy Services
Whether your focus is small molecules, protein biotherapeutics, vaccines, gene therapy, or cell therapy, QPS provides a full range of bioanalytical services to support all of drug development needs from discovery, through clinical development and regulatory filing. Our dedicated, experienced team ensures that drug quantitation studies meet all timelines and regulatory requirements.
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
Whether your focus is small molecules, protein biotherapeutics, vaccines, gene therapy, or cell therapy, QPS provides a full range of bioanalytical services to support all of drug development needs from discovery, through clinical development and regulatory filing. Our dedicated, experienced team ensures that drug quantitation studies meet all timelines and regulatory requirements.
QPS’ extensive Bioanalysis Department provides high quality data and direct access to our technical experts, who conducts analysis of all small molecules, oligonucleotides, peptides and proteins via LC/MS/MS, while the Translational Medicine Department performs analysis, PK or ADA, of all biologics via ELISA, MSD, RT-qPCR, ddPCR.
In addition, our experts in Genomics are leaders in Gene Expression Translation & Profiling and utilizing Genotyping to accelerate pharmaceutical breakthroughs. Genetic biomarkers are important in the drug development process because they can provide information about the potential risk associated with specific genes. Some examples include ApoE genotyping, which is used to determine patient inclusion/exclusion, and patient stratification in Alzheimer’s disease clinical studies.
A flexible approach to bioanalysis
In this application note, QPS describes its range of bioanalytical solutions to support drug development, from drug discovery through clinical development and regulatory filing.
A flexible approach to toxicology and preclinical services
In this application nore, QPS describes how it offers a wide range of toxicity and DMPK studies as well as other preclinical safety tests that are essential for your preclinical drug development programs.
Antibody drug conjugates
In this white paper, QPS describes how it helps improve the quality of your outsourced clinical work and reduces the degree of required oversight.
Plasma protein binding
In this white paper, QPS presents ex vivo protein binding studies that show the type of data that can be generated, and the value of knowing the extent of plasma protein binding in guiding the design and execution of the clinical development plan for a drug.
RNAi therapeutics
In this white paper, QPS describes how it is committed to working with you to advance your RNAi product portfolio in this rapidly developing market segment, for the benefit of patients worldwide.
Therapeutic oligonucleotide metabolite identification, profiling, and quantitation
In this white paper, QPS discusses current advancements in the development of oligonucleotide analogs that can block the activity of selected genetic sequences, making the design of highly specific therapeutic treatments for various diseases possible.
A flexible approach to biotherapeutics and vaccines
In this application note, QPS describes how its leading-edge technologies and pharmaceutical research and development experience creates a business service unit that works efficiently to advance your drug development program.
